➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Express Scripts
Baxter
McKinsey
Harvard Business School

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

Bimatoprost - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for bimatoprost and what is the scope of freedom to operate?

Bimatoprost is the generic ingredient in four branded drugs marketed by Allergan Inc, Akorn, Alembic Pharms Ltd, Apotex Inc, Gland Pharma Ltd, Lupin Ltd, Micro Labs, Sandoz Inc, Somerset Theraps Llc, and Allergan, and is included in sixteen NDAs. There are thirty-two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bimatoprost has two hundred and thirty-one patent family members in thirty-three countries.

There are twelve drug master file entries for bimatoprost. Nine suppliers are listed for this compound. There are five tentative approvals for this compound.

Drug Prices for bimatoprost

See drug prices for bimatoprost

Drug Sales Revenue Trends for bimatoprost

See drug sales revenues for bimatoprost

Recent Clinical Trials for bimatoprost

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mankind Pharma LimitedN/A
CBCC Global ResearchN/A
Medical University of South CarolinaEarly Phase 1

See all bimatoprost clinical trials

Generic filers with tentative approvals for BIMATOPROST
Applicant Application No. Strength Dosage Form
⤷  Try it Free⤷  Try it Free0.03SOLUTION; OPHTHALMIC
⤷  Try it Free⤷  Try it Free0.01%SOLUTION; OPHTHALMIC
⤷  Try it Free⤷  Try it Free0.01%SOLUTION;OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for bimatoprost
Medical Subject Heading (MeSH) Categories for bimatoprost
Paragraph IV (Patent) Challenges for BIMATOPROST
Tradename Dosage Ingredient NDA Submissiondate
LUMIGAN SOLUTION/DROPS;OPHTHALMIC bimatoprost 022184 2011-04-05
LATISSE SOLUTION/DROPS;TOPICAL bimatoprost 022369 2010-05-03
LUMIGAN SOLUTION/DROPS;OPHTHALMIC bimatoprost 021275 2008-12-22

US Patents and Regulatory Information for bimatoprost

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for bimatoprost

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ⤷  Try it Free ⤷  Try it Free
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ⤷  Try it Free ⤷  Try it Free
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ⤷  Try it Free ⤷  Try it Free
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for bimatoprost

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0660716 C300099 Netherlands ⤷  Try it Free PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
0660716 SPC/GB02/035 United Kingdom ⤷  Try it Free PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716 02C0033 France ⤷  Try it Free PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Express Scripts
Baxter
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.